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Iron accumulates in human atherosclerotic lesions but whether it is a cause or simply
a downstream consequence of the atheroma formation has been an open question for
decades. According to the so called “iron hypothesis,” iron is believed to be detrimental for
the cardiovascular system, thus promoting atherosclerosis development and progression.
Iron, in its catalytically active form, can participate in the generation of reactive oxygen
species and induce lipid-peroxidation, triggering endothelial activation, smooth muscle
cell proliferation and macrophage activation; all of these processes are considered
to be proatherogenic. On the other hand, the observation that hemochromatotic
patients, affected by life-long iron overload, do not show any increased incidence
of atherosclerosis is perceived as the most convincing evidence against the “iron
hypothesis.” Epidemiological studies and data from animal models provided conflicting
evidences about the role of iron in atherogenesis. Therefore, more careful studies
are needed in which issues like the source and the compartmentalization of iron will
be addressed. This review article summarizes what we have learnt about iron and
atherosclerosis from epidemiological studies, animal models and cellular systems and
highlights the rather contributory than innocent role of iron in atherogenesis.
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INTRODUCTION
A ROLE FOR IRON IN ATHEROSCLEROSIS: THE “IRON HYPOTHESIS”
The correlation between iron and heart disease was initially pro-
posed by Sullivan in 1981. According to his “iron hypothesis,” iron
overload promotes cardiovascular disease, while on the contrary,
sustained iron depletion/deficiency exerts a primary protective
effect against ischemic heart disease. This theory, continually
debated for more than 30 years, was based on the observation
that male gender is associated with higher risk of cardiovascu-
lar disease, but that the protective effect in women is diminished
after menopause (Sullivan, 1981, 1989). Based on results from the
Framingham study (Kannel et al., 1976), Sullivan first hypoth-
esized that the regular menstrual loss of iron, rather than the
effect of estrogen, protects women against coronary heart disease
(CHD). The failure of postmenopausal estrogen replacement to
prevent coronary events further supported the iron hypothesis
and its link to gender differences in atherosclerosis (Hulley et al.,
1998).
The presence of redox-active iron, as well as high expres-
sion levels of H- and L-ferritin in human atherosclerotic lesions
provided indirect support for the iron hypothesis (Smith et al.,
1992; Pang et al., 1996). L-ferritin levels are increased in coro-
nary arteries from patients with coronary artery disease (CAD),
indicating that iron accumulates in atherosclerotic plaques (You
et al., 2003). Additionally, cholesterol levels in lesions correlate
with iron deposits (Stadler et al., 2004). Within the plaque, iron
deposition and ferritin induction may be observed in endothelial
cells and macrophages in early human lesions, and additionally in
vascular smooth muscle cells (VSMCs) in late lesions.
Iron accumulates in human atherosclerotic lesions (Sullivan,
2009) via different mechanisms. Under normal conditions iron
circulates in the bloodstream bound to its carrier protein trans-
ferrin (Tf). However, non-transferrin bound iron (NTBI) may be
generated during chronic iron overload disorders such as sickle
cell disease, thalassemia and transfusional iron overload (Brissot
et al., 2012). NTBI is thought to be easily accessible to many cell
types within the plaque, likely accumulating in endothelial cells,
macrophages, and VSMCs (Figure 1).
Iron can enter into the atherosclerotic lesion in the form of free
hemoglobin (Hb), that is released upon intravascular hemolysis
or intraplaque hemorrhage (Kolodgie et al., 2003). Intraplaque
hemorrhage originates from leaky neovessels invading the intima
from the vasa vasorum as the intima thicken, and contributes
significantly to the enlargement of the necrotic core (Sakakura
et al., 2013). Increasing evidence indicates that plaque neovascu-
larization and vasa vasorum density accompanied by intraplaque
hemorrhage is a strong marker for plaque vulnerability (Moreno
et al., 2004; Carlier et al., 2005; Virmani et al., 2005; Michel et al.,
2011; Sakakura et al., 2013). Following intraplaque hemorrhage,
red cells can be taken up by macrophages or they burst extracellu-
larly releasing free Hb. Hb is prone to oxidation, especially in the
highly oxidative milieu of the atheroma leading to the formation
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FIGURE 1 | A role for iron in atherosclerotic lesions. Iron accumulates in
the plaque either as inorganic or hemoglobin-bound iron. Inorganic iron in part
derives from circulating transferrin (Tf)-bound iron and non-transferrin-bound
iron (NTBI). NTBI is generated in chronic iron overload conditions, such as in
iron-loading anemia, hereditary hemochromatosis or secondary
hemochromatosis due to blood transfusions. Circulating NTBI is accessible to
many cell types in the atherosclerotic plaque: endothelial cells,
monocytes/macrophages, and vascular smooth muscle cells (VSMCs).
Hemoglobin- and heme-derived iron can access the plaque upon intravascular
hemolysis and intraplaque hemorrhage, affecting endothelial cells and
macrophages. Hemoglobin (Hb), heme and iron promote endothelial
activation, by enhancing adhesion molecule expression. As a consequence,
monocyte recruitment is expected to be increased. Circulating iron and Hb
oxidize LDLs, thus enhancing subendothelial LDL retention and macrophage
progression to foam cells. Iron also affects VSMC proliferation and migration
into the lesion, favoring plaque progression.
of metHb and higher oxidation states such as ferrylHb, which
can release heme (Figure 1). Altogether, Hb oxidation products,
heme and iron exert pro-oxidant and pro-inflammatory effects
targeting different cellular (i.e., endothelial cells, smooth muscle
cells, macrophages) and acellular components (i.e., low-density
lipoprotein, LDL) of the atherosclerotic vessel wall (Figure 1).
The finding that human atherosclerotic plaques contain redox-
active iron, that could promote free radical formation and lipid
peroxidation, further suggested a role for iron in atherosclero-
sis that may be eventually responsible for progressive oxidative
damage in atherosclerotic lesions. This review article summarizes
our current knowledge about the role of Hb, heme, and iron in
atherosclerosis by discussing the results of epidemiological stud-
ies, and observations in animal models and cellular experiments.
ALTERED IRON HOMEOSTASIS AND ATHEROSCLEROSIS:
EPIDEMIOLOGICAL STUDIES, HUMAN CASES
CORRELATION BETWEEN MARKERS OF IRON STORES AND
DEVELOPMENT OF CAD
To evaluate whether iron accumulation in the atherosclerotic
plaque is a cause, rather than a consequence, of cardiovascu-
lar disease, several epidemiological and perspective studies were
conducted since the nineties and many are still ongoing.
The results of several human studies strongly suggested a rela-
tionship between body iron levels and atherosclerosis. According
to these epidemiological studies, high systemic iron levels, moni-
tored by serum ferritin levels or transferrin saturation, positively
correlated with increased risk of myocardial infarction (Salonen
et al., 1992; Morrison et al., 1994; Tuomainen et al., 1998;
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Holay et al., 2012) cardiovascular disease (Rajapurkar et al.,
2011), peripheral arterial disease (PAD) (Menke et al., 2009), and
mortality rates (Lauffer, 1990). This association was stronger in
men with high serum LDL levels, suggesting a synergistic role of
high iron and high LDL levels (Salonen et al., 1992; Morrison
et al., 1994). Finally, a clear proatherogenic role for iron was sug-
gested by the observation that a 10mg/L increase in serum ferritin
level raised the probability of having at least two atherosclerotic
plaques by 3% (Ahluwalia et al., 2010).
Body iron stores correlated with asymptomatic carotid
atherosclerosis in healthy men (Syrovatka et al., 2011), an associ-
ation becomes even more evident in symptomatic atherosclerosis.
Plaques from symptomatic patients showed higher iron concen-
trations, signs of cap rupture and increased cap macrophage
activity compared with asymptomatic plaques (Gustafsson et al.,
2013). This suggests that the presence of iron in carotid plaques
positively correlates with plaque vulnerability for rupture.
Additionally, the description of serum ferritin levels as a risk
indicator of carotid lesion progression highlights a clear associa-
tion between atherosclerosis progression and iron stores (Kiechl
et al., 1997).
In agreement with this, serum iron levels directly correlate
with cardiovascular disease severity. Serum iron levels were sig-
nificantly higher in patients with severe atherosclerosis compared
to those showing normal, mild, and moderate sings of CADs,
thus further strengthening the hypothesis that high iron lev-
els could affect atherosclerosis severity (Bagheri et al., 2013).
Collectively, these epidemiological studies clearly identified high
body iron levels as a risk factor for atherosclerosis and cardiovas-
cular diseases.
Serum ferritin levels are frequently used to assess body
iron status but increasing evidence suggests that this parame-
ter additionally serves as a more general marker of inflamma-
tion (Kalantar-Zadeh et al., 2004; Manousou et al., 2011). Thus,
some studies evaluated the relationships between serum ferritin,
inflammatory cytokines and cardiovascular disease (Haidari et al.,
2001; Depalma et al., 2010). Ferritin levels positively correlated
with IL-6 and C-reactive protein (hsCRP) levels and were higher
in patients that died of acute myocardial infarction vs. survivors,
further supporting a rationale for measurement of ferritin levels
in patients with atherosclerosis.
BLOOD DONATION AND THE RISK OF CAD
The incidence of atherosclerosis in premenopausal women was
less than half of that observed in men of the same age (Kiechl
and Willeit, 1999). The sex difference disappeared within 5
years after menopause, likely due to increased body iron stores.
According to these observations, in 1991 Sullivan proposed that
blood donation could prevent cardiovascular disease (Sullivan,
1991). Several studies confirmed the cardiovascular protective
effect of blood donation. Blood donation was positively associ-
ated with a reduced risk of cardiovascular disease, in particu-
lar in non-smoking men with high serum LDL levels (Meyers
et al., 1997, 2002; Tuomainen et al., 1997; Salonen et al., 1998).
This result was in agreement with the iron hypothesis, accord-
ing to which the protective effect of blood donation would
be more pronounced in men that have a higher body iron
load than women. A first randomized clinical trial (FeAST)
showed that phlebotomy resulted in clinical benefits and reduc-
tion of death in young patients affected by PAD (Sullivan
and Katz, 2007; Zacharski et al., 2007). High-frequency blood
donation was associated with reduced body iron stores and
improved vascular function and blood pressure, reduced oxida-
tive stress, improved markers of cardiovascular risk in blood
donors (Zheng et al., 2005; Houschyar et al., 2012). These find-
ings are complemented by the observation that endothelial dys-
function is attenuated by iron chelation in patient with CAD
(Duffy et al., 2001). Altogether these findings suggest that iron
depletion, by blood donation or iron chelation, significantly low-
ers the risk of cardiovascular disease, thus supporting the iron
hypothesis.
ASSOCIATION OF IRON OVERLOAD AND CAD IN HEMOCHROMATOSIS
If the iron hypothesis is correct, individuals with iron overload
would be expected to show an increased risk and incidence of car-
diovascular diseases, thus being optimal study model to test the
validity of the hypothesis.
An interesting observation comes from the study of American
blacks that compared to American whites and Hispanics are well
known for higher ferritin levels throughout their entire life, likely
explained by nutritional and genetic factors rather than increased
iron intake (Zacharski et al., 2000). Interestingly, the incidence
of CHD is higher in African–American than in white men and
women (Gillum et al., 1997; Sacco et al., 1998), suggesting an
association between body iron and cardiovascular disease.
Hereditary hemochromatosis (HH) is a genetic disorder asso-
ciated with progressive iron overload, resulting in oxidative stress
and organ failure. HH is more common among individuals of
Northern European descent and is caused by inherited muta-
tions in proteins implicated in iron transport and regulation, such
as the upstream regulators of hepcidin, the human hemochro-
matosis protein (HFE), hemojuvelin, transferrin receptor (TfR)-
2, as well as hepcidin and ferroportin (FPN) (Hentze et al.,
2010).
Hemochromatotic patients show vascular dysfunction and
increased expression of adhesion molecules that positively cor-
relates to iron overload and NTBI levels (Gaenzer et al., 2002;
Kartikasari et al., 2006; Van Tits et al., 2007). These patients fur-
ther show functional and structural alterations in midsize muscle
arteries. In particular, arterial wall thickness is increased before
the onset of cardiovascular complications, suggesting that this
is an early abnormality in HH. This alteration is reverted by
phlebotomy-induced iron depletion, which can also improve the
endothelium-dependent vasodilation and the initial radial artery
wall stiffening associated with HH (Failla et al., 2000; Gaenzer
et al., 2002).
Different cohort studies reported a significantly greater risk
of myocardial infarction, cerebrovascular mortality and cardio-
vascular mortality in carriers of the HFE mutation (Cys282Tyr)
(Roest et al., 1999; Tuomainen et al., 1999; Rasmussen et al.,
2001). Additionally, patients with genetic hemochromatosis have
significant eccentric hypertrophy of the radial artery, although
not showing arterial hypertension or evidence of cardiovascular
disease.
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In contrast to the above reported studies, others failed to
find an association between hemochromatosis and the pres-
ence or frequency of atherosclerosis and did not succeed in
establishing a link between body iron stores and cardiovascu-
lar diseases in human populations (Miller and Hutchins, 1994;
Sullivan and Zacharski, 2001; Munoz-Bravo et al., 2013). The
disagreement among epidemiological studies may result from
variations in the validity and reliability of the indicators of iron
status. Additionally, the magnitude of the relative risk associated
with iron overload might be small, thus the association being
obscured by stronger risk factors. Further prospective and experi-
mental studies are needed to confirm the association between the
iron status and atherosclerosis.
THE “REFINED IRON HYPOTHESIS”: A PROTECTIVE ROLE FOR
IRON-DEPLETED MACROPHAGES IN ATHEROSCLEROSIS
Controversial results from epidemiological studies investigating
different types of atherosclerotic events and using various mark-
ers for body iron levels present a confusing picture regard-
ing the iron hypothesis. In addition, several studies failed
to observe an increased risk or incidence of cardiovascu-
lar events in hemochromatotic patients, thus further increas-
ing the confusion concerning an eventual association between
iron overload and atherosclerosis (reviewed in Munoz-Bravo
et al., 2013). Finally, the description of a potentially protective
effect of hemochromatosis against atherosclerosis and cardio-
vascular diseases was perceived as a “paradox” and considered
as clear evidence against the iron hypothesis (Miller and
Hutchins, 1994; Sullivan and Zacharski, 2001;Munoz-Bravo et al.,
2013). On the basis of these observations Sullivan presented
a refinement of his “iron hypothesis” (Sullivan and Zacharski,
2001).
Since then the peptide hormone hepcidin has been identified
as the master regulator of iron homeostasis. Hepcidin inhibits
iron export by binding to FPN and promoting its degrada-
tion. By inhibiting FPN, hepcidin prevents iron release from
enterocytes into the bloodstream and decreasing iron release
from macrophages, thereby reducing the amount of iron sys-
temically available. HH is hallmarked by low levels of hep-
cidin and/or increased expression of the iron exporter FPN.
Therefore, in hemochromatotic patients the FPN-hepcidin cir-
cuitry is impaired, leading to increased duodenal iron absorp-
tion and reduced iron retention in macrophages (Hentze et al.,
2010; Ganz and Nemeth, 2011). Considering the key role of the
macrophages in atherogenesis, the selective iron depletion in this
cell type was proposed as a mechanism of protection against foam
cell formation and atherosclerotic lesion progression (Figure 2).
According to this view, the hypothesis postulated by Sullivan that
iron depletion protects against atherosclerosis may apply even to
hemochromatotic individuals.
According to this view, hepcidin levels may act as a poten-
tial iron-dependent risk factor for atherosclerosis by regulat-
ing macrophage iron accumulation and atherosclerotic plaque
progression (Figure 2). Recently, hepcidin was suggested as a
predictor of carotid atherosclerosis. Serum ferritin was found
to associate with vascular damage, common carotid thickness
and presence of carotid plaques in all patients but not those
showing a reduction in hepcidin levels due to heterozygous HFE
mutations (Valenti et al., 2011b). Additionally, hepcidin levels
and macrophage iron positively correlate with the release of
IL-6 and macrophage chemoattractant protein 1 (MCP-1), and
vascular damage in high-risk individuals (Valenti et al., 2011a).
Collectively, these findings suggest an involvement of iron-loaded
macrophages in inflammation and vascular alterations. On the
other hand, monocytes from hemochromatotic patients showed
reduced ability to accumulate iron and reduced upregulation of
MCP-1 and IL-6 (Valenti et al., 2011a). The anti-inflammatory
properties of iron-depleted macrophages may help to explain the
lack of increased incidence of atherosclerosis in hemochromatotic
patients.
Anyway, a direct and definitive demonstration of the refined
iron hypothesis in human is still lacking and further studies are
needed to fully elucidate the impact of macrophage-stored iron,
as well as circulating iron and tissue-stored iron on human lesion
formation and progression.
THALASSEMIAS AND SICKLE CELL ANEMIA
β-thalassemia and sickle cell anemia are hereditary blood disor-
ders characterized by anomalies in the synthesis of the β-globin
chains of Hb. β-thalassemic and sickle patients show increased
plasma iron turnover, iron absorption and tissue iron deposition.
Additionally, they have frequent hemolytic events that lead to the
release of Hb and heme into the circulation, further increasing
the amount of redox-active iron available for the production of
reactive oxygen species and lipid peroxidation (Livrea et al., 1998;
Brizzi et al., 2002). The release of Hb upon hemolytic events
and the enhanced absorption of iron, to support inappropriate
erythropoiesis, contribute to the pathogenesis of vasculopathy,
a well-known predisposing factor for cardiovascular diseases.
Moreover, these patients, usually presenting with severe anemia,
require regular red blood cell transfusions (Vichinsky, 2005), fur-
ther exacerbating iron overload and iron-driven oxidative stress
(McLeod et al., 2009).
Iron-dependent peroxidative tissue injury results in arterial
stiffness and dysfunction, frequently occurring in thalassemic
patients (Kremastinos et al., 1999; Hahalis et al., 2008). Iron over-
load in patients with beta-thalassemia major lead to alterations
in the arterial structures and in the thickness of the carotid arter-
ies (Cheung et al., 2002; Tantawy et al., 2009). Moreover, carotid
thickness positively correlated with age, Hb, ferritin and choles-
terol levels in these patients (Cheung et al., 2006; Tantawy et al.,
2009). As a result, CAD is a quite common cardiovascular com-
plication in thalassemia (Ramakrishna et al., 2003; Ferrara and
Taylor, 2005; Aessopos et al., 2007). Patients on a regular transfu-
sion regimen progressively develop clinical manifestations of iron
overload associated with heart dysfunction and left ventricular
failure (Borgna-Pignatti et al., 2004). Interestingly, iron chelation
therapy in thalassemia patients improves arterial function and
stiffness (Cheung et al., 2008).
Ischemic complications are the major causes of morbidity and
mortality in patients with sickle cell disease (Platt et al., 1994;
Switzer et al., 2006). Ischemic events in these patients have been
attributed to the effects of Hb polymerization, resulting in sickled
cells trapped in themicrocirculation (Francis and Johnson, 1991).
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FIGURE 2 | Schematic overview of the “refined iron hypothesis”:
a role for macrophage-retained iron in atherosclerosis. Iron can
accumulate in macrophages as inorganic iron and Hb-iron, upon
erytrophagocytosis or hemolysis. Once stored in the cell, iron can
be made available to the bloodstream via FPN-mediated export.
According to the refined iron hypothesis, high hepcidin levels are
considered a risk factor for plaque progression and destabilization.
Hepcidin is known to bind to FPN, thus promoting its degradation
and blocking iron export. This increases intracellular ROS levels and
decreases cholesterol efflux. As a result, the oxidative status alters
and LDL accumulation occurs, promoting foam cell formation,
inflammation and eventually plaque instability.
Nevertheless, different factors other than red blood cell sickling,
could contribute to these events, atherosclerosis being one of this.
SCD is an uncommon risk factor for atherosclerosis. However,
in the last decades, together with the increased life expectancy of
SCD patients, the risk to develop atherosclerosis is significantly
increasing. Endothelial dysfunction, hyperhomocysteinemia and
activation of platelets are the most likely mechanisms for the
development of atherosclerosis in SCD patients (Elsharawy et al.,
2009). The presence of excessive circulating Hb, heme, and iron
in SCD could have in principle a crucial role in atherosclerosis
development, even though a clear experimental proof of this is
still missing. Conversely, a paradoxical protective effect of SCD on
atherosclerosis and thrombosis was observed in ApoE-null mice
transplanted with bone marrow from mice carrying the sickle
cell mutation. This effect was abolished by inhibition of HO-
1, suggesting that this protection relies on the activity of this
enzyme, whose induction is sustained in SCD, due to the high
circulating Hb and heme levels (Wang et al., 2013). These obser-
vations have the limit that mice were analyzed after 23–28 weeks
from bone marrow transplantation, giving an idea of the onset of
atherosclerosis but not of the late phases of the disease, in which
HO-1 activity could be eventually overwhelmed, thus promoting
atherosclerosis progression.
The most common sites of atherosclerosis in these patients
are represented by large cerebral arteries (Rothman et al., 1986).
Approximately 75% of strokes in sickle cell disease are the result of
occlusion of cerebral vessels (Moran et al., 1998). Also pulmonary
and splenic arteries are common sites of atherosclerosis in sickle
cell disease. One-third of the sickle patients had histological evi-
dence of medial hypertrophy and intimal proliferation in these
arteries (de Chadarevian et al., 2001; Graham et al., 2007).
Therefore, thalassemia and sickle cell anemia patients are con-
sidered at high atherogenic risk in view of the perturbation of
the Hb/heme/iron metabolism that predisposes these patients to
oxidative status alterations (Belcher et al., 1999; Switzer et al.,
2006).
HAPTOGLOBIN POLYMORPHISM AND CAD
Extracellular Hb may exert proatherogenic effects via differ-
ent mechanisms. Free Hb scavenges nitric oxide, an impor-
tant vasodilator and signaling molecule (reviewed in Rother
et al., 2005). Moreover, oxidized Hb species trigger pro-oxidant
(reviewed in Balla et al., 2005) and pro-inflammatory effects
on vascular endothelium (Silva et al., 2009), and cause lipid-
peroxidation (Jeney et al., 2002; Potor et al., 2013).
Efficient mechanisms have evolved to remove extracellular Hb
from the circulation to limit its deleterious effects. Haptoglobin
(Hp) is an acute-phase plasma protein with the primary func-
tion to capture cell-free Hb and chaperon it to macrophages for
degradation (reviewed in Alayash, 2011). Hp binding facilitates
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the removal of Hb from circulation via endocytosis through the
CD163 macrophage scavenger receptor (Kristiansen et al., 2001).
The Hp gene is polymorphic in humans, whereby the two
functional alleles (hp1 and hp2) can form three genotypes: Hp1-
1, Hp2-1, and Hp2-2 with heterogeneous protein structure and
functional differences (reviewed in Goldenstein et al., 2012).
Differences between antioxidant properties of Hp1-1 and Hp2-2
were examined. An early study showed that Hp1-1 protein is more
potent in inhibiting the oxidative actions of extracorpuscular
Hb (Melamed-Frank et al., 2001). Contradictory, a recent study
described no differences between the two phenotypes in protect-
ing against Hb-driven toxicity (Lipiski et al., 2013). When applied
in vivo following Hb injection both Hp1-1 and Hp2-2 attenuate
Hb-induced blood pressure response with equal efficacy, restrict
trans-endothelial diffusion of extracellular Hb equally, and pre-
vent Hb redistribution and renal iron deposition in the same way
(Lipiski et al., 2013). Both phenotypes show similar abilities to
stabilize the ferryl Hb state, to restrict heme release from the com-
plex, and to prevent Hb-driven LDL oxidation in vitro (Lipiski
et al., 2013). Immunomodulatory effects of the two phenotypes
were compared as well. The Hp1-1-Hb complex induces more
robust anti-inflammatory macrophage signaling, leading to the
secretion of anti-inflammatory cytokines than that of Hp2-2-Hb
complex (Philippidis et al., 2004; Landis et al., 2013).
The Hp polymorphism was investigated as a possible genetic
determinant in cardiovascular disease. These epidemiologic stud-
ies revealed that the Hp2-2 genotype is a risk factor for car-
diovascular complications in both type I and type II diabetic
patients (reviewed in Costacou and Levy, 2012). In particular, the
Hp2-2 genotype is associated with elevated amounts of iron in
atherosclerotic carotid plaques, accompanied by increased levels
of oxidation-specific epitopes, increased macrophage infiltration
and decreased VSMCs, all events promoting plaque instabil-
ity (Lioupis et al., 2011, 2012; Purushothaman et al., 2012).
In addition, the Hp2-2 genotype is associated with increased
circulating oxLDL levels when compared to Hp1-1 or Hp2-1
genotypes (Brouwers et al., 2004). A correlation between theHp2-
2 genotype, carotid plaque instability and increased risk of major
cardiovascular diseases was recently described (Ijas et al., 2013).
Collectively, these findings suggest that detoxification of extra-
cellular Hb byHp acts in an atheroprotective manner. In addition,
the Hp2-2 genotype represents a non-modifiable risk factor for
cardiovascular diseases. Because Hp1-1 and Hp2-2 inhibit the
oxidative actions of extracorpuscular Hb equally, therefore dis-
ease association is most probably explained by other functions or
properties of the Hp molecule.
HEME OXYGENASE-1 (HO-1) AND CARDIOVASCULAR DISEASE
Heme oxygenases catabolize heme to equimolar amounts of
biliverdin, carbon monoxide, and free iron, followed by the
conversion of biliverdin into bilirubin by biliverdin reductase
(Singleton and Laster, 1965; Tenhunen et al., 1968). HO-1 is
a stress-inducible isoform of heme oxygenases, encoded by the
hmox-1 gene which possesses antioxidant, anti-apoptotic and
anti-inflammatory properties (reviewed in Gozzelino et al., 2010;
Durante, 2011). These protective mechanisms partially rely on
the ability of HO-1 to extract iron from heme. The released
iron induces the expression of ferritin, the 24-subunit complex
of heavy (H) and light (L) chains, with enormous iron-storage
capacity (Eisenstein et al., 1991; Harrison and Arosio, 1996).
In addition, both bilirubin and CO, the other two end prod-
ucts of heme degradation exhibit direct anti-oxidant and anti-
inflammatory activities (Gozzelino et al., 2010).
An important, but somewhat neglected function of HO-
1 is its role in iron recycling (Poss and Tonegawa, 1997).
Erythrophagocytosis, subsequent HO-1-mediated heme degrada-
tion and iron release from macrophages is a major mechanism
in iron recycling, accounting for about 90% of total body iron
turnover (reviewed in Hentze et al., 2010).
Accumulating evidences suggest the protective role of HO-
1 in atherosclerotic vascular disease (reviewed in Chan et al.,
2011). Both the antioxidant bilirubin and the vasodilator CO
may contribute to this atheroprotective effect (Siow et al., 1999;
Mayer, 2000; Parfenova et al., 2012; Erkan et al., 2013). Low
bilirubin levels are associated with endothelial dysfunction and
increased intima-media thickness (Erdogan et al., 2006), whereas
high plasma bilirubin concentrations are linked to low incidence
of cardiovascular disease (Schwertner et al., 1994) and stroke
(Kimm et al., 2009). Differences in plasma bilirubin levels may
arise from the variation of HO-1 activity in humans.
In the human hmox-1 promoter a GT repeat microsatellite
polymorphism exists, leading to higher hmox-1 transcriptional
activity and subsequently higher HO-1 expression in individu-
als having shorter GT repeats compared to subjects with longer
GT repeats. A number of studies investigated the relationship
between this gene polymorphism and the risk of cardiovascu-
lar disease, with conflicting results. Some studies revealed that
shorter GT repeats in the hmox-1 promoter region are associated
with lower incidence and/or progression of CAD (Kaneda et al.,
2002; Liang et al., 2013), whereas others argue against a relevant
role of this polymorphism in cardiovascular diseases (Lublinghoff
et al., 2009).
Progressive atherosclerotic lesion destabilization with subse-
quent plaque rupture is a key event predisposing to acute throm-
bus formation and coronary artery occlusion (Schwartz et al.,
2007). Autopsy studies reveal that the risk of plaque rupture
mainly depends on the composition of the plaque rather than
its size (Kolodgie et al., 2004). Severe macrophage infiltration,
a necrotic core and a thin fibrous cap are the main character-
istics of vulnerable plaques (Kolodgie et al., 2004). In humans,
HO-1 expression is increased in atherosclerotic lesions and closely
correlates with plaque instability and pro-inflammatory markers.
The observation that HO-1 induction reverses plaque progres-
sion from a vulnerable plaque to amore stable phenotype suggests
that HO-1 expressionmay act as a compensatory atheroprotective
mechanism (Cheng et al., 2009).
By contrast, HO-1 deficiency in humans leads to severe vas-
cular pathologies (Yachie et al., 1999). A 6-year old boy with
inactivating mutations of the HO-1 gene presented with severe
intravascular hemolysis associated with persistent endothelial
damage. Autopsy examination revealed the presence of aortic
fatty streaks and fibrous plaques at this young age, highlight-
ing the atheroprotective function of HO-1 (Yachie et al., 1999).
More recently, another case of HO-1 deficiency in a young girl
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was reported, with evidence of severe endothelial damage, as
suggested by raised inflammatory markers, von Willebrand fac-
tor and coagulopathy (Radhakrishnan et al., 2011). Since free
circulating heme promotes endothelial damage, the lack of func-
tional HO-1 likely results in a form of vasculitis or endothelial
injury syndrome. This may therefore increase their susceptibility
to develop atherosclerosis.
Taken together, these findings prove a crucial role for HO-1
in the maintenance of vascular homeostasis and counteraction of
atherosclerosis.
ALTERED IRON HOMEOSTASIS AND ATHEROSCLEROSIS:
ANIMAL MODELS
IRON OVERLOAD AND IRON DEFICIENCY IN ATHEROSCLEROSIS
The effect of iron in atherogenesis was tested using different
hypercholesterolemic animal models. In an initial study that
intramuscular administration of iron dextrane augmented the
formation of atherosclerotic lesions in hypercholesterolemic rab-
bits (Araujo et al., 1995). In contrast, another group using the
same rabbit model described that iron dextrane injection sig-
nificantly decreased lesion formation by about 50% by reduc-
ing plasma cholesterol levels (Dabbagh et al., 1997). Kirk et al.
observed a reduction (about 50%) in plaque area in apoE defi-
cient mice fed with a 2% carbonyl iron containing standard diet
in spite of that dietary iron overload caused a modest (30%) rise
in plasma triglyceride and cholesterol levels (Kirk et al., 2001).
Other studies took the opposite approach and examined
the effect of iron restriction on atherogenesis. In this regard,
atherosclerotic lesions in mice fed a low-iron diet were signifi-
cantly smaller than those found in control littermates (Lee et al.,
1999). Reduced plaque size in the low-iron group was associ-
ated with lower levels of circulating autoantibodies to oxLDL,
and the diminished occurrence of thiobarbituric acid reactive epi-
topes in the lesions (Lee et al., 1999). This was explained by the
observation that dietary iron restriction increases plaque stabil-
ity via elevated collagen and reduces matrix metalloproteinase-9
expressions in the lesion (Lee et al., 2003). Consistently, iron
chelation by DFO lowers the iron content of the lesions and
inhibits atherosclerotic lesion development in cholesterol-fed rab-
bit (Minqin et al., 2005) as well as in apoE deficient mice
(Zhang et al., 2010). Other than an effect on atherosclerosis, sev-
eral studies showed that iron depletion by chelation significantly
reduces endothelial activation and vascular dysfunction in ani-
mal models (Ishizaka et al., 2005). Recently, a combined therapy
of iron chelator and antioxidant was observed to restore iron-
induced brain vascular dysfunction in rats (Sripetchwandee et al.,
2014), supporting the idea that iron promotes earlier steps in
atherogenesis.
HEMOCHROMATOSIS MODELS
Although there is support for the idea that iron is detrimental for
atherosclerosis, the validity of the original iron hypothesis has not
been tested inmodels of genetic iron overload, such as hemochro-
matotic mice. To date, several mouse models of hemochromato-
sis are available, such as HFE-null, Hamp-null, HJV-null, and
BMP6-null mice (Fleming et al., 2011) but atherosclerosis pro-
gression has not been assessed in any of them. Future studies will
have to dissect the contribution of systemic iron overload and
macrophage iron deficiency in hemochromatotic mouse models
for atherosclerosis in order to better understand the outcome of
the epidemiological studies.
ANIMAL MODELS TO ASSESS THE IMPACT OF MACROPHAGE IRON ON
ATHEROSCLEROSIS
The key role of macrophages in atherosclerosis was exten-
sively studied in animal models. Lipid-laden foam cells are
macrophages derived from circulating monocytes that migrate
into the vessel wall. Inhibition ofmonocytemigration, by disrupt-
ing a variety of chemokine/chemokine receptor interactions, was
shown to inhibit atherosclerosis development. The osteopetrotic
(op) mouse, spontaneously deficient in macrophage-colony stim-
ulating factor (M-CSF), displayed a reduction of 86% in plaque
volume, demonstrating the essential role of macrophages in
atherogenesis (Smith et al., 1995). Quite recently, a CD11b–
diphtheria toxin receptor transgenic mouse line was generated,
whereby diphtheria toxin administration conditionally ablates
monocytes/macrophages (Stoneman et al., 2007). In atherogen-
esis experiments, diphtheria toxin markedly decreased monocyte
numbers by 50% and altered plaque development and compo-
sition, reducing collagen content and necrotic core formation,
thus demonstrating that monocytes/macrophages are critical for
atherogenesis.
The crucial role of macrophages in atherosclerosis raised the
possibility of selective intraplaque macrophage depletion achiev-
able as a specific therapeutic intervention to counteract plaque
progression. This approach now gains increasing attention in car-
diovascular medicine. Several successful strategies have recently
been reported to induce macrophage cell death in atherosclerotic
plaques (Martinet and De Meyer, 2007). Its feasibility is currently
debated and object of several studies, aimed at locally deleting
macrophages, without affecting this cell type in other tissue com-
partments. However, local therapies can be administered only for
a relatively short time, with the limitation that macrophages may
reinfiltrate the plaque after treatment.
Assessment of the impact of macrophage-associated iron
on atherosclerosis could eventually provide additional mecha-
nisms/pathways that could be targeted in macrophages to pre-
vent/reduce atherosclerosis. Animal studies were initiated to
evaluate the role of iron in macrophages, thus revisiting the
iron hypothesis. Although not tested in hemochromatotic mice,
atherosclerosis was studied in mice with macrophage iron deple-
tion triggered by drug administration. The pharmacological sup-
pression of hepcidin in mice decreased macrophage iron content,
and increased cholesterol efflux, thus resulting in reduced foam
cell formation (Saeed et al., 2012). In particular, the reduction
of macrophage-associated iron levels lowered the formation of
ROS and increased the expression of cholesterol transporters,
namely ABCA1 and ABCG1. This leads to improved lipid efflux
by macrophages, correlating with reduced foam cell formation
and atherosclerosis (Figure 2). This approach is limited by the use
of a BMP signaling pathway inhibitor to achieve hepcidin sup-
pression. BMP signaling inhibitors are in fact expected to effect
on many other biological processes involved in the formation of
the atherosclerotic plaque, other than those directly dependent on
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hepcidin reduction. Future studies that apply drugs that directly
and specifically reduce hepcidin expression or that counteract its
activity are needed to examine whether hepcidin suppression by
itself affects progression of atherosclerosis.
In agreement with these findings, hepcidin recently emerged
as a positive regulator of atherosclerotic plaque destabilization,
via regulating macrophage iron homeostasis (Li et al., 2012).
Hepcidin production in the carotid artery was achieved by ade-
noviral infection in a mouse model of accelerated atherosclerosis.
Although a change in plaque size was not observed, hepcidin
overexpression significantly affected plaque composition, increas-
ing intraplaque macrophages and decreasing VSMCs and col-
lagen amounts. Additionally, hepcidin overexpression increased
trapped iron as well as oxidized-LDL levels in intraplaque
macrophages. This correlated with increased oxidative stress and
expression of pro-inflammatory cytokines by macrophages and
enhanced plaque vulnerability, suggesting that hepcidin plays a
critical role in plaque destabilization.
Collectively, these findings indicate that the interactions of
hepcidin, trapped iron, and accumulated lipids are critical for
proatherosclerotic activation of macrophages leading to plaque
destabilization (Figure 2). The suppression of hepcidin by spe-
cific shRNA exerts effects opposite to those reported above.
These studies described a unique role for hepcidin in promoting
atherosclerosis progression and plaque instability and provided
evidence of a protective function of the iron-spared macrophage,
at least partially clarifying the paradoxical issues observed in
hemochromatosis.
A complementary approach to test the effect of iron-loaded
macrophages on atherosclerosis was recently pursued (Kautz
et al., 2013). Atherosclerosis was studied in the flatiron (ffe)
mouse (Zohn et al., 2007), a model that specifically accumu-
lates iron in macrophages. Contrary to the refined iron hypoth-
esis, atherosclerosis was not increased in mice with elevated
macrophage iron. In addition, increased macrophage iron levels
triggered by parenteral iron administration also failed to pro-
mote atherosclerosis. These findings dispute that macrophage
iron loading could be an aggravating factor in the pathogenesis
of atherosclerosis.
EFFECTS OF HO-1 IN ANIMAL MODELS OF ATHEROSCLEROSIS
The role of HO-1 in atherosclerotic lesion formation was
first investigated in apoE deficient mice, overexpressing HO-1.
Overexpression of HO-1 in the vasculature was achieved by direct
injection of an adenovirus expressing HO-1 (Adv-HO-1) into
the left ventricles of anesthetized animals. HO-1 overexpression
inhibits lesion formation and reduces iron overload in apoE defi-
cient mice (Juan et al., 2001). Reduced iron deposition in aortic
tissues of Adv-HO-1-treated mice might be explained by the
observation that HO-1 overexpression augments iron recycling
from cells (Ferris et al., 1999). To further examine the role of
HO-1 in atherogenesis, mice deficient in both HO-1 and apoE
were generated. When compared to apoE deficient mice these
double knock-out mice exhibited accelerated and more advanced
lesion formation in response to a cholesterol rich diet (Yet et al.,
2003). Interestingly, aged HO-1 knock-out mice exhibit severe
aortitis and coronary arteritis with mononuclear cell infiltration
accompanied by fatty streak formation, even on a standard chow
diet (Ishikawa et al., 2012).
Expression of HO-1 is strongly regulated by its substrate heme,
in a Bach1-mediated manner. Bach1 is a transcriptional repressor
of the hmox-1 gene that becomes inactive and undergoes ubiqiti-
nation and degradation upon heme binding (Zenke-Kawasaki
et al., 2007). Consequently, deletion of the bach1 gene leads to
sustained HO-1 expression in various tissues. The effect of bach1
deletion in atherosclerosis was studied in Bach1 apoE double defi-
cient mice (Watari et al., 2008). In these mice HO-1 was upreg-
ulated in the vasculature, mainly in the vascular endothelium
(Watari et al., 2008). Elevated HO-1 expression was accompa-
nied by reduced plaque area compared with that in apoE deficient
mice, supporting the anti-atherogenic nature of HO-1 (Watari
et al., 2008). Overexpression of HO-1 inhibited lesion progres-
sion into vulnerable plaques, whereas inhibition of HO-1 activity
augmented plaque vulnerability (Cheng et al., 2009).
Biological effects of a wide variety of molecules depend on
the upregulation of HO-1 by these compounds (Bach, 2005).
Accordingly, there are several anti-atherosclerotic compounds
that exert their protective effects via the induction of HO-1. For
example the anti-oxidant probucol, has been shown to protect
from atherosclerosis by a HO-1 pathway that is independent of
radical scavenging in various models of vascular diseases (Wu
et al., 2006). Recently, HO-1 was found to be the molecular tar-
get of Tanshinone IIA, a lipophilic bioactive compound extracted
from Salvia miltiorrhiza Bunge that exert anti-atherogenic effect
via suppressing cholesterol accumulation in macrophages (Liu
et al., 2014). In addition, the polyphenolic compound quercetin
as well attenuates endothelial dysfunction and atherosclerosis in
apoE deficient mice in a HO-1 dependent manner (Shen et al.,
2013).
Taken together, these results support a protective function for
HO-1 in atherosclerotic lesion formation and progression.
EFFECT OF IRON ON MAIN PLAYERS IN ATHEROGENESIS
LIPID METABOLISM AND LDL OXIDATION
Elevated iron stores reflected by increased plasma ferritin levels
are positively correlated with the prevalence of certain diseases
such as metabolic syndrome, diabetes and obesity (Jehn et al.,
2004, 2007; Lecube et al., 2008; Sun et al., 2008). All of these
diseases are associated with abnormal lipid metabolism, but until
recently there were few studies addressing whether elevated iron
levels and lipid metabolism are directly correlated. A first study
showed that HH associated with primary hypertriglyceridemia
(Solanas-Barca et al., 2009), which can be improved by periodic
therapeutic phlebotomy (Casanova-Esteban et al., 2011). In rats
with dietary iron overload a significant increase in triglycerides,
free cholesterol, cholesteryl ester, and high-density lipoprotein-
cholesterol levels was observed (Brunet et al., 1999). By con-
trast, intraperitoneal injection of iron-dextrane enhanced serum
triglyceride levels but not serum cholesterol levels in an inde-
pendent study (Silva et al., 2008). Excess iron directly modulates
activities of several key enzymes for cholesterol and triglyc-
eride homeostasis—e.g., 3-hydroxy-3-methylglutaryl coenzyme
A reductase, cholesterol 7alpha-hydroxylase, acyl-CoA: choles-
terol acyltransferase and lipoprotein lipase - which might explain
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perturbations of lipid metabolism in conditions of iron overload
(Brunet et al., 1999).
Other than affecting lipid metabolism, iron mediates the
oxidative modification of LDL, a clear contributing factor to
the pathogenesis of atherosclerosis (Heinecke et al., 1984). The
molecular mechanism of iron-catalyzed LDL oxidation was
extensively studied. Redox active iron that undergoes oxidation
and reduction is an absolute necessity to catalyze lipid peroxida-
tion (Lynch and Frei, 1993; Miller et al., 1993). Iron-mediated
oxidation of LDL is dependent on superoxide anion (O−•2 ) that
acts as a Fe3+ reducing agent, but requires neither H2O2 nor pro-
duction of hydroxyl radical (OH•) by the Fenton reaction (Lynch
and Frei, 1993).
The unlikely existence of iron in free catalytically active form
in normal body fluids initiated the search for physiologically more
relevant iron compounds with the ability to oxidize LDL. In fact
most of the iron in the human body is found in heme that serves
as a prosthetic group in Hb and other heme proteins. This ubiq-
uitous iron compound is a very efficient catalyst of LDL oxidation
(Balla et al., 1991a). Studies revealed that initiation and prop-
agation of heme-induced lipid-peroxidation is independent of
Fenton chemistry similarly to that of iron-mediated LDL oxida-
tion. The initial interaction between heme and H2O2 might lead
to the formation of ferryl and perferryl radicals, those can be
responsible for initiating lipid peroxidation (Klouche et al., 2004).
During heme-mediated LDL oxidation, oxidative scission of the
heme ring occurs and iron is released (Balla et al., 1991a). Both
heme degradation and LDL oxidation are effectively inhibited by
lipid soluble antioxidants and iron chelators (Balla et al., 1991a;
Pocsi et al., 2008).
Several lines of evidence suggest that heme-mediated oxi-
dation of LDL occurs in vivo. High amount of heme in the
plasma of the HO-1 deficient boy was correlated with exten-
sive LDL oxidation (Jeney et al., 2002). During heme-mediated
LDL oxidation heme reacts with proline and arginine residues in
apolipoprotein B-100 and a unique oxidation product, gamma-
glutamyl semialdehyde is formed, that is subsequently reduced
to 5-hydroxy-2-aminovaleric acid (HAVA). HAVA is a hallmark
of heme-mediated LDL oxidation, as other agents known to trig-
ger LDL oxidation, such as HOCl, H2O2 alone or in combination
with Cu2+ or Fe2+ induce only minor HAVA formation (Julius
and Pietzsch, 2005). Elevated concentrations of HAVAwere found
in LDL of patients with impaired glucose tolerance and with
diabetes mellitus suggesting that heme-mediated LDL oxidation
occurs in these patients (Julius and Pietzsch, 2005).
Cell-free Hb when oxidized releases heme and induces oxida-
tive modification of LDL (Jeney et al., 2002). This effect was
abolished by the heme-scavenging protein Hx and by Hp or
cyanide, agents that either bind free heme or strengthen the
heme-globin bond, highlighting the role of heme release in this
process (Miller et al., 1996; Jeney et al., 2002). Recently a feed-
forward process in atheromatous lesions with the interactions of
atheroma lipids and cell free Hb was described. This vicious cycle
includes lipid-hydroperoxide mediated oxidation of Hb, sponta-
neous heme release, oxidative heme scission, iron release, and
further lipid peroxidation (Nagy et al., 2010; Jeney et al., 2013;
Potor et al., 2013).
Collectively, these results confirm that excess iron, heme, and
cell-free Hb act in an atherogenic manner.
ENDOTHELIAL CELL ACTIVATION AND DYSFUNCTION
Upon steady-state condition, endothelial cells provide an
antithrombotic and antiadhesive surface in the vasculature. Low-
grade inflammation is a characteristic of the atherosclerotic
lesions in which endothelial cell activation occurs, triggering
vasoconstriction, thrombosis as well as leukocyte adhesion, and
transmigration (Libby, 2002). This pro-inflammatory response
relies on the upregulation of a variety of genes encoding vaso-
constrictive, pro-thrombic, pro-inflammatory, chemotactic, and
adhesive molecules (reviewed in Pober and Sessa, 2007). Redox-
sensitive mechanisms involving the activation of redox-regulated
transcription factor nuclear factor-kB (NF-kB) have been impli-
cated in the expression of these vascular inflammatory molecules
(Marui et al., 1993; Kunsch and Medford, 1999).
Accumulating evidences suggest the critical role of redox active
iron in mediating the pro-inflammatory response in endothe-
lial cells. Chelation of iron by DFO leads to decreased induction
of E-selectin, vascular cell adhesion molecule-1 (VCAM-1), and
intercellular adhesion molecule-1 (ICAM-1) in endothelial cells
stimulated by tumor necrosis factor alpha (TNF alpha) (Zhang
and Frei, 2003). Switching to in vivo models, iron chelation
inhibits the lipopolysaccharide-mediated induction of soluble
cellular adhesion molecules, monocyte chemoattractant protein-
1 (MCP-1) and activation of NF-kB in mice (Zhang et al.,
2010). In humans, iron chelation by DFO improves nitric oxide-
mediated endothelium-dependent vasodilation in patients with
CAD, highlighting a role for iron in impaired nitric oxide action
in atherosclerosis (Duffy et al., 2001).
The direct association between excess iron and endothelial dys-
function has been established upon physiological and patholog-
ical conditions. Administration of iron into healthy individuals
provoked endothelial dysfunction accompanied by increased gen-
eration of superoxide radical in whole blood (Rooyakkers et al.,
2002). Hemodialysis (HD) patients who receive intravascular iron
along with erythropoiesis-stimulating agents to treat functional
iron deficiency and subsequent anemia, as well as iron-overload
patients, provide a unique opportunity to study the effect of iron
on vascular function. There are conflicting data regarding the
effect of iron on vascular function, cardiovascular risk and over-
all mortality in HD patients. Serum ferritin was reported as a
marker of mortality in HD patients, but whether ferritin levels
were regulated by iron in these patients is not clear (Kalantar-
Zadeh et al., 2001). High serum ferritin level in HD patients
(>600μg/L) is associated with increased overall 4-year mortal-
ity even in the absence of infection (Kletzmayr and Horl, 2002).
A cohort study concluded that iron supplementation at a dose of
1000mg or less over 6 month does not have any adverse effect,
whereas iron supplementation at higher doses is associated with
elevated morbidity (Feldman et al., 2004).
Recently, more mechanistic studies were performed to show
the involvement of endothelial dysfunction in iron-triggered car-
diovascular complications. Intravenous administration of iron
increased the levels of circulating soluble adhesion molecules
in HD patients which was associated with higher risks for
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cardiovascular events (Kuo et al., 2012). Consistently, endothe-
lial cells treated with iron sucrose, a widely used iron drug,
changed their morphology and showed an increased ability to
recruit monocyte (Kamanna et al., 2012). Iron sucrose treatment
causes marked reduction in acetylcholine-mediated relaxation in
rat aorta rings, thus further confirming the detrimental effect of
iron on endothelial function (Kamanna et al., 2012). Iron over-
load diseases are associated with the presence of NTBI in the
serum. In serum from hemochromatosis patients, NTBI levels
were found to be positively correlated with the expressions of
adhesion molecules, ICAM-1, VCAM-1, and E-selectin but not
to the inflammatory marker CRP (Kartikasari et al., 2006).
Hemolytic diseases are also associated with endothelial dys-
function, therefore several studies addressed whether cell free Hb
or heme can harm endothelial cells directly in these pathologies.
Heme strongly sensitizes endothelial cells to oxidant-mediated
killing and its plasma scavenger, Hx, completely inhibits this
effect (Balla et al., 1991b). Hb when oxidized to metHb can
transfer heme to the endothelium and exert the same sensitizing
effect as free heme (Balla et al., 1993). More recently globin-
globin cross-linked Hb multimers were identified in complicated
atherosclerotic lesions (Nagy et al., 2010). The formation of
these species can be triggered by inorganic and organic perox-
ides and involves the generation of ferrylHb and globin radicals
(reviewed in Jeney et al., 2013). Interestingly, these globin-globin
cross-linked Hb multimers are the exclusive species inducing
pro-inflammatory response in endothelial cells in vitro. As a
pro-inflammatory agonist, globin-globin cross-linked Hb mul-
timers trigger the formation of intercellular gaps disrupting the
integrity of the endothelial cell monolayer, induce the expression
of adhesion molecules, E-selectin, ICAM-1, and VCAM-1 leading
to increased monocyte adhesion (Silva et al., 2009; Potor et al.,
2013).
Recently, the study of mouse models of hemolytic diseases
(β-thalassemia and sickle cell disease mice) proved that heme
largely contributes to endothelial activation and dysfunction and
cardiovascular alterations (Tolosano et al., 2010; Vinchi and
Tolosano, 2013). These effects can be strongly counteracted by
the administration of an Hx-based therapy (Vinchi et al., 2008,
2013). Most of these effects have been described to rely on heme
ability to activate TLR4 in endothelial cells. Heme-mediated TLR4
activation leads to Weibel-Palade body (WPB) mobilization and
degranulation, thus promoting the expression of P-selectin and
VWF, and NF-κB activation in endothelial cells in vitro and ves-
sel wall surfaces in vivo (Belcher et al., 2014). By activating TLR4
pathway, heme triggers vascular stasis and occlusion, common
complications associated with hemolytic disorders such as sickle
cell disease. TLR4-null mice transplanted with sickle bone mar-
row do not exhibit heme-induced vaso-occlusion and activation
of WPB/NF-κB. The ability of Hb and heme to induce stasis is
abolished by the administration of the Hb and heme scavengers,
Hp and Hx in a mouse model of SCD (Belcher et al., 2014). In
addition heme has been recently described as a trigger of the acute
chest syndrome, one of the major complications associated with
SCD. In a sickle mouse model, respiratory failure due to ACS
was avoided by treatment with recombinant Hx. The activation
of TLR4 by heme in vascular tissues was likely responsible for
this lethal type of acute lung injury. Pharmacologic inhibition
of TLR4 protected sickle mice from heme-induced ACS (Ghosh
et al., 2013).
These recent findings highlight a crucial role for the TLR4-
activated signaling pathway in Hb/heme-mediated activation of
endothelial cells and macrophages. From the point of view of
atherosclerosis, a role for TLR4 in the initiation and progression
of the disease is widely recognized. TLR4 is expressed on the cell
surface of themain cell types involved in atherosclerosis, endothe-
lial cells, platelets and macrophages. Its activation is required
to enhance the expression of adhesion molecules and cytokines
(e.g., MCP1), thus promoting the recruitment of monocytes and
initiating the inflammatory response. The enhanced cytokine
and chemokine release by TLR4 activation could stimulate EC
and VSMC migration and proliferation, thus accelerating plaque
progression (Pasterkamp et al., 2004). Additionally, oxLDL up-
regulate TLR4 expression and induce cytokine expression at
least partially via TLR4 activation (Pasterkamp et al., 2004; den
Dekker et al., 2010). Also platelets participate in atherogenesis
and show clear signs of increased activity in individuals with
established cardiovascular and thrombotic disease. Increased acti-
vation of platelets via TLR4 binding could increase the risk of
atherosclerosis and thrombosis (Jayachandran et al., 2010) and
heme could potentially promote this event. Some mouse models
and human studies also support a role of TLR4 in the pro-
gression of atherosclerotic disease. Individuals with TLR4 defi-
ciency may be at increased risk for infection but at lower risk
for cardiovascular disease (Jayachandran et al., 2010). Besides
heme scavenging by Hp and Hx, targeting TLR4 as a sig-
naling receptor downstream of heme could be an alternative
therapeutic approach to reduce heme-driven pro-atherogenic
effects.
Heme and oxidized Hb species can also threaten vascular
endothelial cell integrity indirectly by their ability to mediate the
oxidative modification of LDL (reviewed in Balla et al., 2005).
Lipid hydroperoxides are transiently formed during LDL oxi-
dation and responsible mostly for oxLDL-mediated endothelial
damage and for initiation of redox signaling (Nagy et al., 2005,
reviewed in Chapple et al., 2013).
Altogether these finding indicate that excess iron, extracel-
lular Hb and heme have detrimental effects on the vascular
endothelium leading to endothelial dysfunction.
THE EFFECT OF IRON ON MACROPHAGE POLARIZATION AND
FUNCTION
During atherogenesis, blood monocytes are recruited to the vas-
cular endothelium and attracted to the subendothelial space
where the deposition of LDL occurs. These monocytes are later
differentiated into macrophages and foam cells. Atherosclerosis
macrophages are one of the most important cell populations, as
they contribute to the progression of the lesions.
Macrophages are innate immune system cells therefore they
exhibit great plasticity. Different stimuli and environments can
lead to diverse phenotypes. Their functions comprise inflamma-
tory responses, antimicrobial activity, tissue remodeling and iron
recycling (Khallou-Laschet et al., 2010; Leitinger and Schulman,
2013).
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Macrophages are key players in the regulation of iron home-
ostasis as they recycle 20–25mg of iron per day from senescent
erythrocytes. Macrophages engulf aged or damaged erythrocytes
and catabolize heme via HO-1 activity. Heme-derived iron is
then exported from phagocytic vesicles by the natural resistance-
associated macrophage protein 1 (NRAMP1) and divalent metal
transporter 1 (DMT1) expressed within phagolysosomal mem-
branes. Iron is either stored coupled to ferritin or exported as
ferrous iron via FPN, the only known iron exporter (Hentze
et al., 2010). Interestingly, several studies demonstrated thatmuch
of the iron within plaques is associated with macrophages and
foam cells. The exact source of iron still needs to be elucidated.
However, it is well known that an important contribution is made
by Hb-contained iron that is released from microhemorrhage
within the plaque (Boyle et al., 2009; Saeed et al., 2012).
The identification of different macrophage subtypes that
polarize in response to a specific microenvironment (Leitinger
and Schulman, 2013), in both human and murine atheroscle-
rotic lesions, raised the possibility that iron itself could affect
macrophage plasticity. A putative involvement of iron in the
polarization of some macrophage subtypes has been recently
demonstrated in atherosclerosis (Figure 3).
Two major subtypes of macrophages have been exten-
sively studied and described: the classical activation (M1) and
the alternative activation (M2) macrophages (Figure 3). M1
macrophages are polarized after exposure to IFNγ and/or micro-
bial products such as LPS. These macrophages are characterized
by a strong pro-inflammatory activity with the production
of several inflammatory cytokines: IL-1β, IL-6, IL-8, IL-12,
and TNFα (Butcher and Galkina, 2012). In terms of iron
metabolism, M1 macrophages are prone to a low turn-over
of iron with low expression of CD163, HO-1, FPN and high
expression of ferritin, suggesting an iron retention phenotype
with decreased iron recycling and export capacity (Recalcati
et al., 2010). In chronic venous leg ulcers and wound heal-
ing models, macrophage iron overload induces an unrestrained
pro-inflammatory M1 phenotype, via enhanced production of
TNFα and hydroxyl radicals, suggesting that iron accumula-
tion in macrophages contributes to a pro-inflammatory pheno-
type (Sindrilaru et al., 2011). Similarly, macrophage exposure
to heme could lead to a pro-inflammatory activation of these
cells. In fact, heme has been described as an extracellular signal-
ing molecule able to affect the innate immune response thanks
to its ability to bind and activate TLR4. By activating TLR4
heme, induces the secretion of (TNF-alpha) by macrophages
(Figueiredo et al., 2007), suggesting that heme retains the abil-
ity to polarize macrophages toward an M1 rather an M2 phe-
notype. Whether plaque-associated macrophages are polarized
toward the M1 or M2 phenotype in hemolytic sickle animal
models or patients still needs to be investigated to address this
point.
In atherosclerosis M1 macrophages were detected in both
human and mouse lesions, in the lipid core of the plaque.
M1 macrophages were the prevalent macrophage subtype in
advanced lesions (Khallou-Laschet et al., 2010). It is postulated
that M1 macrophages might contribute to the formation of the
necrotic core, since inflammatory macrophages are prone to
FIGURE 3 | High macrophage plasticity in atherosclerosis. In the
atherosclerotic plaque, macrophages differentiate into different
phenotypes. The two extreme phenotypes are represented by M1 and M2
macrophages. M1 macrophages show strong pro-inflammatory properties,
thus potentially being involved in lesion progression. M1 macrophages
show high expression levels of iNOS, MHCII, and inflammatory cytokines,
such as IL-6 and TNF-a. M2 macrophages are considered anti-inflammatory
and are involved in tissue repair and remodeling. M2 specific markers are
Arginase 1, Ym1, and IL-10. The M2 phenotype is reported as
anti-atherogenic. In addition, several other macrophage phenotypes are
observed in the atherosclerotic plaque. Mhem macrophages originate as a
consequence of intraplaque hemorrhage and are endowed with high Hb
handling ability. These anti-atherogenic macrophages express high levels of
the heme-degrading enzyme HO-1 and the Hp-Hb scavenger receptor
CD163. Additionally, Mheme macrophages express the cholesterol
exporters ABCA1 and ABCG1, thus efficiently activating reverse cholesterol
efflux. Mox macrophages are generated upon oxidized phospholipid
stimulation. They show anti-oxidant properties, as they express genes
involved in the anti-oxidant responses such as HO-1, Txnrd1, and Srxn1.
Their potentially athero-protective effect still needs to be demonstrated. M4
macrophages differentiate in response to the chemo-attractant CXCL4, thus
showing pro-inflammatory and pro-atherogenic effects. These
macrophages express low levels of CD163 and high levels of MHCII and
CD86. M1 and M4 macrophages promote, while M2 and Mhem
macrophages counteract foam cell formation, thus having opposite effect
on atherosclerosis progression.
evolve in foam cells, eventually leading to apoptosis and cell
content release. Moreover, the release of TNFα, IL-1β, IL-6 and
other inflammatory cytokines by M1 macrophages in the lesion
environment may contribute to the activation of endothelial cells
(increasing the expression of LFA-1, VCAM-1, ICAM-1, CCL2,
CD62P, and CD62E) and smooth muscle cells (increasing the
expression of CCL2, CCL9, CX3CL1, CXCL10, CXCL16, and
VCAM-1) and an overall increase in oxidative stress by the pro-
duction of reactive oxygen and nitrogen species. In addition,
M1 macrophages are associated with the response of Th1 lym-
phocytes, which is in accordance to an increased inflammatory
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response (Butcher and Galkina, 2012). All these events are
expected to promote atherosclerotic plaque progression.
The alternative M2 macrophages are polarized after expo-
sure to IL-4 or IL-13 and display an anti-inflammatory phe-
notype. M2-like macrophages have been described in wound
healing as well as in association with tumors and with human
carotid atherosclerotic plaques (Bouhlel et al., 2007). This subtype
of macrophages has enhanced capacity for phagocytosis, tissue
remodeling and matrix metalloproteases production (Martinez
et al., 2006; Mosser and Edwards, 2008). In contrast to M1, M2
macrophages have higher expression of CD163, HO-1 and FPN
and low expression of ferritin, suggesting that these macrophages
have an iron release phenotype with increased iron uptake, recy-
cling and export but low iron retention (Recalcati et al., 2010;
Cairo et al., 2011). In atherosclerosis, M2macrophages are mainly
found in early lesions and are characterized by the expression
of CD68 and mannose receptor (Chinetti-Gbaguidi et al., 2011).
They preferentially localize in the area of the plaque overlying the
lipid core (Khallou-Laschet et al., 2010). M2macrophages are less
susceptible to become foam cells and they also display a lower
ability to handle lipids and to export cholesterol, due to the down-
regulation of the cholesterol exporter ABCA1 and the LDL carrier
apoE. Also upregulation of genes involved in phagocytosis sug-
gests that M2 macrophages in atherosclerosis have an enhanced
phagocytic activity by clearing up cellular debris and dead cells
(Chinetti-Gbaguidi et al., 2011). M2 macrophages are associated
with a Th2 type response (Butcher and Galkina, 2012). These
macrophages do not contribute to the activation of endothelial
cells or smooth muscle cells since they have anti-inflammatory
properties (Kleemann et al., 2008). Altogether—less suscepti-
bility to become foam cells, high phagocytic activity and anti-
inflammatory properties—place these macrophages as protective
for the atherosclerotic lesion development.
Recently, new subtypes of macrophages have been described in
the context of atherosclerosis, supporting the idea of an increasing
diversity of macrophage subsets within the lesions.
The platelet-derived chemokine CXCL4 promotes the dif-
ferentiation of monocytes to macrophages toward an M4
macrophage subtype (Gleissner et al., 2010b) (Figure 3). There
is no doubt that CXCL4 is important for atherosclerosis since the
deletion of the PF4 gene that encodes CXCL4 reduces atheroscle-
rotic lesions in apoE deficient mice (Sachais et al., 2007). M4
macrophages display a distinct transcriptome when compared
to M1 and M2 macrophages. The major characteristic of this
subtype relies on the downregulation of CD163, the Hp-Hb scav-
enger receptor, which indicates that M4 macrophages are not able
to clear Hb after plaque hemorrhage (Gleissner et al., 2010a,b).
The incapacity of Hb uptake is consistent with the absence of
HO-1 upregulation which has a protective and anti-inflammatory
effect in atherosclerotic lesion (Gleissner, 2012). This also might
have some implication for iron handling but further studies are
necessary to characterize this macrophage subtype regarding iron
turnover. In addition M4 macrophages showed reduced expres-
sion of cholesterol scavenger receptors, leading to a decreased
ability to clear modified LDL. Immunohistochemistry of human
post-mortem coronary arteries revealed the presence of CD68+
CD163+ as well as CD68+ CD163− macrophages, showing
a correlation in the expression levels of CD163 and CXCL4
(Gleissner et al., 2010a). Whether this macrophage subtype pro-
motes or protects against atherosclerotic plaque progression still
needs to be addressed. On the basis of their reduced Hb clearance
ability, a detrimental role of M4 macrophages in atherosclerosis
could be speculated. Future research will be required to estab-
lish whether M4 macrophages represent a promising therapeutic
target in human atherosclerosis.
Atherosclerotic lesions are characterized by the accumulation
of oxidized phospholipids that also play a role in macrophage
polarization. A novel macrophage phenotype denominated Mox
macrophages was identified in the lesions of mice deficient for
the LDL receptor (Kadl et al., 2010) (Figure 3). Moxmacrophages
were identified in atherosclerotic plaques in mice and accounted
for 30% of all CD11b+/F4/80+ cells in established lesions. In
vitro treatment of bone marrow-derived macrophages (BMDMs)
with oxidized phospholipids reproduced differentiation toward
this macrophage subtype that is distinct from both M1 and M2
subtypes. Considering the pro-oxidant action of iron, increased
iron levels would be expected to enhance lipid oxidation, thus
promoting Mox polarization. Whether this occurs in conditions
of body iron overload has not been demonstrated.
Mox macrophages show a characteristic expression profile,
including the upregulation of HO-1, thioredoxin reductase1 and
sufiredoxin-1, whose expression is dependent on the redox-
sensitive transcription factor Nrf2 (Kadl et al., 2010; Butcher
and Galkina, 2012). These Mox-specific genes may have impor-
tant functions in controlling oxidative status in an oxidizing
environment and protecting cells from dying in oxidatively dam-
aged tissue. It was demonstrated that failure of Nrf2 expression
leads to various diseases related to oxidative stress, inflammation,
and xenobiotic metabolism in mice. Based on these findings, a
protective role of Nrf2-driven Mox macrophages in atherogene-
sis would be expected. Surprisingly, a recent study showed that
Nrf2-null mice were protected against diet-induced atherosclero-
sis. Whether these Nrf2-driven Mox macrophages contribute to
the initiation or progression of atherosclerotic lesion formation
remains to be investigated.
Intraplaque hemorrhage is one of the key events in advanced
atherosclerotic lesions leading to iron accumulation and increased
oxidative stress, thus contributing to lesion development.
Erythrophagocytosis is an important source of iron in plaque-
associated macrophages and increased ferritin correlates with
macrophage infiltration in human atheroma (Yuan et al., 1996).
The recent description of hemorrhage-associated macrophages
in atherosclerotic lesions further confirmed that hemorrhage-
derived Hb is a source of iron for intraplaque macrophages and
directs their polarization into a specialized phenotype, able to
handle highHb/iron amount (Boyle et al., 2009; Finn et al., 2012).
These macrophages show high Hb handling capacity and anti-
atherogenic properties and were named Hemorrhage-associated
macrophages (HA-mac), Hb-stimulated macrophages, M(Hb) or
heme-directed macrophages (M-hem) (Figure 3).
Macrophages associated with hemorrhage areas were charac-
terized as CD163 high and HLA-DRlow (Boyle et al., 2011b).
Moreover, as a consequence of enhanced Hb clearance, HA-mac
macrophages have increased HO-1 and FPN expression, leading
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to facilitated heme catabolism and reduced intracellular free iron.
Thus, they show antioxidative characteristics, increased expres-
sion of cholesterol exporters and resist foam cell formation both
in vivo and in response to cholesterol loading. The reduction
in intracellular free iron available for ROS formation causes
increased expression of cholesterol exporters, via the activation of
the LXRs (liver X receptors) pathways. HA-mac macrophages are
distinct from the macrophages found in the lipid core and seem
to play an atheroprotective role. In vitro stimulation of monocytes
with Hb-Hp complexes showed a differentiation toward an HA-
mac phenotype, suggesting that Hb released upon hemorrhage
might model monocytes recruited to the lesion toward a specific
HA-mac subtype (Boyle et al., 2011b). After treatment of human
blood monocytes with heme HO-1and CD163 are upregulated, a
process depending onNrf2 and the activating transcription factor
1 (Boyle et al., 2011a). Altogether, these findings suggest that iron-
spared macrophages may have a protective role, as postulated
by Sullivan, and that the pharmacological manipulation of iron
homeostasis may be a promising target to increase macrophage
reverse cholesterol transport, thus limiting atherosclerosis.
Mhem macrophages exemplify how iron can affect
macrophage differentiation and function, in such a way that they
can handle large amounts of Hb and iron, thus limiting iron-
mediated oxidative effects and preventing lesion progression.
In atherosclerosis, macrophage activity and iron metabolism
might be intrinsically connected. It is interesting to note that
macrophage polarization is driven according to the specific
microenvironment of the atherosclerotic lesion. The description
of the different macrophage subtypes reported above suggests that
also iron, in the form of Hb or via LDL oxidation, can differen-
tially affect macrophage polarization. How broad is the range of
macrophage subtypes generated in response to iron and how these
subtypes contribute to atherosclerosis progression is not clear yet.
Further studies are required to estimate the contribution of dif-
ferent iron sources to macrophage polarization and their impact
on the atherosclerosis process.
THE EFFECT OF IRON ON VSMC PHENOTYPE SWITCH
VSMC are the predominant cell type of the medial layer of
the vessel wall. Under physiological conditions, VSMC show
high contractility and a low proliferation rate. These proper-
ties are essential for VSMC to perform its primary function,
contraction and dilatation of vessels to regulate blood pres-
sure and flow. However, VSMC are not terminally differentiated
cells but show the capacity to switch to synthetic, inflamma-
tory, osteochondrogenic or macrophage-like, phenotypes upon
certain stimuli. The synthetic phenotype is characterized by loss
of contractility, increased motility and high proliferation rate
(Campbell and Campbell, 1985). Synthetic VSMC are involved
in fibrous cap formation during atherogenesis. Inflammatory
VSMC phenotype is defined by cytokine secretion (e.g., IL-8,
IL-6) and cell adhesion molecule expression (e.g., VCAM-1),
that can regulate monocyte/macrophage adhesion and recruit-
ment (Orr et al., 2010). Under certain pathological condi-
tion, VSMCs can undergo phenotypic transition into osteoblast-
like cells, whereby they synthesize excessive extracellular matrix
with parallel loss of their original function (Jono et al., 2000;
Giachelli et al., 2001; Giachelli, 2003), reviewed in Sallam
et al. (2013). Osteoblast specific markers are present in calcified
atherosclerotic lesions, highlighting the relevance of these events
in atherosclerosis (Dhore et al., 2001; Engelse et al., 2001). Finally,
VSMC can differentiate into macrophage-like cells. These cells are
enlarged and characterized by lipid inclusions in the cytoplasm
with immunoreactivity to α-smooth muscle actin and vimentin,
specific markers of VSMC. These cells are present in human
atherosclerotic lesions (Vukovic et al., 2006)
Some effort was made to study the effect of iron on the pheno-
type switching of VSMC. Iron chelation by desferoxamine (DFO)
significantly inhibited VSMC proliferation, a hallmark of the
synthetic phenotype in vitro (Porreca et al., 1994; Wong et al.,
2012), although opposing results show that iron decrease VSMC
growth (Mueller et al., 2006). Iron chelation inhibits the patho-
logical vascular remodeling response induced by balloon injury
and pulmonary hypertension (Porreca et al., 1994; Wong et al.,
2012). Accumulating evidence indicates that heme, and in par-
ticular, products of heme catabolism by HO-1 regulate VSMC
growth (reviewed in Durante, 2003). Carbon monoxide directly
inhibits VSMC proliferation by arresting cells in the G0/G1 phase
of the cell cycle, whereas biliverdin and bilirubin induce VSMC
apoptosis (Morita et al., 1997; Liu et al., 2002; Peyton et al., 2002).
Recently, by studying the effect of iron on osteochondro-
genic differentiation of VSMC, iron was reported to inhibit
inorganic phosphate (Pi)-mediated osteoblastic transition and
subsequent mineralization of VSMCs in vitro (Zarjou et al.,
2009). Importantly, iron inhibited the Pi-mediated increase in the
expression of core binding factor-1 (Cbfa-1), the key osteoblast-
specific transcription factor orchestrating the production of
osteoblast-specific proteins, such as alkaline phosphatase and
osteocalcin (Zarjou et al., 2009). Ferritin was identified as the
major protective molecule behind iron-mediated inhibition of
mineralization. The inhibitory effect of ferritin is strictly depen-
dent on its ferroxidase activity but not on its iron-storage ability
(Zarjou et al., 2009). Although a direct evidence of a role for iron
in calcification in vivo is lacking, recently it has been described
that iron and calcium show a highly significant spatial inverse
correlation within the atherosclerotic lesions (Rajendran et al.,
2012).
Although increasing evidence suggests the critical role of
VSMC phenotype switch in atherogenesis, the role of iron in
these mechanisms still remains to be elucidated. Further in vitro
and in vivo studies are essential to clarify the particular role of
iron in differentiation of VSMC into synthetic, inflammatory,
osteochondrogenic, or macrophage-like phenotypes.
CONCLUSIVE REMARKS
Over the last 30 years, several studies in animals and humans
assessed the effect of increased body iron levels on atheroscle-
rosis, yielding conflicting results. In the last decade, our
understanding of Hb and iron biology underwent a radical
revision. This significantly helped in understanding the athero-
genic effects of iron and iron-containing molecules. Numerous
experiments support the idea that oxidized Hb, Heme, and
iron—by interacting with plaque lipids, promoting endothe-
lial dysfunction, dictating macrophage polarization, modulating
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VSMC phenotype and proliferation—may affect the atherogenic
process. Complex systems have evolved to control and dispose
cell-free Hb, heme, and iron but these systems may be eventu-
ally overwhelmed upon excessive hemorrhage or hemolysis and
upon pathological iron overload. However, to date, the impact
of iron on atherosclerosis is still debated. Future studies are
required to clearly address whether iron overload is a risk fac-
tor for atherosclerosis and what iron source - systemic, tissue
or macrophage iron—mainly affects the atherosclerotic process.
Comprehensive understanding the role of iron on atherogene-
sis may lead to the development of improved diagnostics and
therapeutics meant to interrupt the pathologic actions of excess
iron.
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